Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL Study: Consolidative Radiotherapy After Tisagenlecleucel in r/r DLBCL
jRCTs033250553Recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Primary endpoint: Complete response rate at 3 months. Started Dec 2025; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCTs033250553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs033250553.